Application of Eculizumab in children with atypical hemolytic uremic syndrome / 中华实用儿科临床杂志
Chinese Journal of Applied Clinical Pediatrics
; (24): 1351-1353, 2018.
Article
em Zh
| WPRIM
| ID: wpr-696594
Biblioteca responsável:
WPRO
ABSTRACT
Atypical hemolytic uremic syndrome (aHUS) is associated with a poorer prognosis,and an increased risk for end-stage renal disease (50%) or death (25%).There are about 50% of patients with aHUS associated with dysfunctional complement regulation.Eculizumab,a monoclonal anti-C5 antibody,prevents C5 cleavage and the formation of C5a and C5b-9,thus inhibiting complement activation via 3 pathways and its terminal product formation.Therefore,it is applied to treat complement-mediated aHUS in children and its application improved the prognosis of aHUS.Eculizumab has been recommended as first-line treatment in children with complement-mediated aHUS by an international consensus.In this paper,the application of Eculizumab in children with atypical hemolytic uremic syndrome are reviewed briefly.
Texto completo:
1
Índice:
WPRIM
Idioma:
Zh
Revista:
Chinese Journal of Applied Clinical Pediatrics
Ano de publicação:
2018
Tipo de documento:
Article